Epstein‑Barr virus infection mediated TP53 and Bcl‑2 expression in nasopharyngeal carcinoma pathogenesis

Vatte,Chittibabu; Al-Amri,Ali M; Cyrus,Cyril; Chathoth,Shahanas; Ahmad,Arafat; Alsayyah,Ahmed; Al-Ali,Amein

doi:10.3892/mco.2021.2422

Epstein‑Barr virus infection mediated TP53 and Bcl‑2 expression in nasopharyngeal carcinoma pathogenesis

Authors:
- Chittibabu Vatte
- Ali M Al-Amri
- Cyril Cyrus
- Shahanas Chathoth
- Arafat Ahmad
- Ahmed Alsayyah
- Amein Al-Ali
View Affiliations

Affiliations: Department of Biochemistry, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 31441, Kingdom of Saudi Arabia, Department of Internal Medicine, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Al-Khobar 31952, Kingdom of Saudi Arabia, Department of Pathology, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Al-Khobar 31952, Kingdom of Saudi Arabia
Published online on: October 19, 2021 https://doi.org/10.3892/mco.2021.2422
Article Number: 260
Copyright: © Vatte et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epstein Barr virus (EBV) stimulates neoplastic transformation of nasopharyngeal epithelial cells through various molecular mechanisms, predominantly affecting inactivation of tumor‑suppressor genes and activation of oncogenes. EBV infection is a major risk factor for nasopharyngeal carcinoma (NPC), yet its role in the carcinogenesis is not clear. EBV infection alters the expression of antiapoptotic proteins and tumor suppressor proteins. Therefore, this study investigated the correlation between EBV infection status with B cell lymphoma‑2 (Bcl‑2) and TP53 protein expression amongst laryngeal and nasopharyngeal cancer cases. This study was performed using 22 nasopharyngeal and 11 laryngeal cancer cases. EBV infection status, TP53 and Bcl‑2 protein expression was studied using immunohistochemistry. The majority of the laryngeal cancer cases exhibited a poor prognosis and presented low Bcl‑2 expression. A total of 22.7% cases were infected with EBV in the NPC cases. Upregulated TP53 expression was associated with EBV infection in the NPC cohort, and EBV infection was correlated with TP53 upregulation in the patients with NPC, suggesting mutual regulation between TP53 and EBV.

View Figures

View References

1	Leemans CR, Snijders PJF and Brakenhoff RH: The molecular landscape of head and neck cancer. Nat Rev Cancer. 18:269–282. 2018.PubMed/NCBI View Article : Google Scholar
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
3	Epstein MA and Barr YM: Cultivation in vitro of human lymphoblasts from burkitt's malignant lymphoma. Lancet. 1:252–253. 1964.PubMed/NCBI View Article : Google Scholar
4	Old LJ, Boyse EA, Oettgen HF, Harven ED, Geering G, Williamson B and Clifford P: Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells. Proc Natl Acad Sci USA. 56:1699–1704. 1966.PubMed/NCBI View Article : Google Scholar
5	de Schryver A, Friberg S Jr, Klein G, Henle W, Henle G, De-Thé G, Clifford P and Ho HC: Epstein-Barr virus-associated antibody patterns in carcinoma of the post-nasal space. Clin Exp Immunol. 5:443–459. 1969.PubMed/NCBI
6	zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P and Santesson L: EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature. 228:1056–1058. 1970.PubMed/NCBI View Article : Google Scholar
7	Cao Y: EBV based cancer prevention and therapy in nasopharyngeal carcinoma. NPJ Precis Oncol. 1(10)2017.PubMed/NCBI View Article : Google Scholar
8	Shahani T, Makvandi M, Samarbafzadeh A, Teimoori A, Ranjbar N, saki N, Nikakhlagh S, Neisi N, Hosseini Z, Pourrezaei S, et al: Frequency of Epstein Barr virus type 1 among nasopharyngeal carcinomas in Iranian patients. Asian Pac J Cancer Prev. 18:327–331. 2017.PubMed/NCBI View Article : Google Scholar
9	Young LS and Dawson CW: Epstein-Barr virus and nasopharyngeal carcinoma. Chin J Cancer. 33:581–590. 2014.
10	Khan G and Hashim MJ: Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010. Infect Agent Cancer. 9(38)2014.PubMed/NCBI View Article : Google Scholar
11	Varmus H and Kumar HS: Addressing the growing international challenge of cancer: A multinational perspective. Sci Transl Med. 5(175cm2)2013.PubMed/NCBI View Article : Google Scholar
12	Holmes D: The cancer-virus cures. Nat Med. 20:571–574. 2014.PubMed/NCBI View Article : Google Scholar
13	Lieberman PM: Virology. Epstein-Barr virus turns 50. Science. 343:1323–1325. 2014.PubMed/NCBI View Article : Google Scholar
14	Tsao SW, Tsang CM and Lo KW: Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci. 372(20160270)2017.PubMed/NCBI View Article : Google Scholar
15	Sahoo R, Chittibabu V, Patil G, Rao S, Thakur S, Dhondalay G, Kulkarni AJ, Banerjee A, Ajaikumar BS, Korlimarla A, et al: Relationship between molecular markers and treatment response in a retrospective cohort of Indian patients with primary carcinoma of the larynx. Oral Oncol. 45:e216–e221. 2009.PubMed/NCBI View Article : Google Scholar
16	Bieging KT, Mello SS and Attardi LD: Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 14:359–370. 2014.PubMed/NCBI View Article : Google Scholar
17	Kastenhuber ER and Lowe SW: Putting p53 in Context. Cell. 170:1062–1078. 2017.PubMed/NCBI View Article : Google Scholar
18	Wang Q, Lingel A, Geiser V, Kwapnoski Z and Zhang L: Tumor suppressor p53 stimulates the expression of epstein-barr virus latent membrane protein 1. J Virol. 91:e00312–17. 2017.PubMed/NCBI View Article : Google Scholar
19	Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ and Green DR: The BCL-2 family reunion. Mol Cell. 37:299–310. 2010.PubMed/NCBI View Article : Google Scholar
20	Kelly PN and Strasser A: The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 18:1414–1424. 2011.PubMed/NCBI View Article : Google Scholar
21	Wenmei S, Yanming L, Fenping W, Hongsheng G, Lixia L, Suwen Z, Zhennan L, Rong L and Zhixiong Y: Bcl-2 regulation by miR-429 in human nasopharyngeal carcinoma in vivo. Int J Clin Exp Pathol. 9:5998–6006. 2016.
22	World Medical Association. World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 310:2191–2194. 2013.PubMed/NCBI View Article : Google Scholar
23	Kanno M, Narita N, Fujimoto Y, Wakisaka N, Yoshizaki T, Kodaira T, Makita C, Sato Y, Yamazaki K, Wakaoka T, et al: Third epidemiological analysis of nasopharyngeal carcinoma in the central region of Japan from 2006 to 2015. Cancers (Basel). 11(1180)2019.PubMed/NCBI View Article : Google Scholar
24	Ngan HL, Wang L, Lo KW and Lui VWY: Genomic landscapes of EBV-associated nasopharyngeal carcinoma vs. HPV-associated head and neck cancer. Cancers (Basel). 10(210)2018.PubMed/NCBI View Article : Google Scholar
25	Breda E, Catarino RJ, Azevedo I, Lobão M, Monteiro E and Medeiros R: Epstein-Barr virus detection in nasopharyngeal carcinoma: Implications in a low-risk area. Braz J Otorhinolaryngol. 76:310–315. 2010.PubMed/NCBI
26	Al-Shidhani SNS, Al-Sinawi S, Al-Bahri M, Al-Kindi M and Mabruk M: Determination of the expression of latent Epstein Barr virus in Omani nasopharyngeal carcinoma patients. Biomed Pharmacol J. 14:257–265. 2021.
27	Wu L, Li C and Pan L: Nasopharyngeal carcinoma: A review of current updates. Exp Ther Med. 15:3687–3692. 2018.PubMed/NCBI View Article : Google Scholar
28	Yang HJ, Cho YJ, Kim HS, Chang MS, Sung MW and Kim WH: Association of p53 and BCL-2 expression with Epstein-Barr virus infection in the cancers of head and neck. Head Neck. 23:629–636. 2001.PubMed/NCBI View Article : Google Scholar
29	Sarac S, Akyol MU, Kanbur B, Poyraz A, Akyol G, Yilmaz T and Sungur A: Bcl-2 and LMP1 expression in nasopharyngeal carcinomas. Am J Otolaryngol. 22:377–382. 2001.PubMed/NCBI View Article : Google Scholar
30	Tulalamba W and Janvilisri T: Nasopharyngeal carcinoma signaling pathway: An update on molecular biomarkers. Int J Cell Biol. 2012(594681)2012.PubMed/NCBI View Article : Google Scholar
31	Muller PA and Vousden KH: p53 mutations in cancer. Nat Cell Biol. 15:2–8. 2013.PubMed/NCBI View Article : Google Scholar
32	Tabyaoui I, Serhier Z, Sahraoui S, Sayd S, Cadi R, Bennani OM, Benider A, Zamiati S and Tahiri JN: Immunohistochemical expression of latent membrane protein 1 (LMP1) and p53 in nasopharyngeal carcinoma: Moroccan experience. Afr Health Sci. 13:710–717. 2013.PubMed/NCBI View Article : Google Scholar
33	Zhang P, Wu SK, Wang Y, Fan ZX, Li CR, Feng M, Xu P, Wang WD and Lang JY: p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study. Oncol Lett. 9:113–118. 2015.PubMed/NCBI View Article : Google Scholar
34	Liu J, Liu Y, Zhang Z, Sun H, Ji X, Li B, Zhou X and Gai P: Prognostic value of the Epstein-Barr virus and tumor suppressor gene p53 gene in nasopharyngeal squamous cell carcinoma. J Cancer Res Ther. 15:426–436. 2019.PubMed/NCBI View Article : Google Scholar
35	Menke DM, Griesser H, Moder KG, Tefferi A, Luthra HS, Cohen MD, Colon-Otero G and Lloyd RV: Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate. Am J Clin Pathol. 113:212–218. 2000.PubMed/NCBI View Article : Google Scholar
36	Niemhom S, Kitazawa S, Murao S, Kunachak S and Maeda S: Co-expression of p53 and bcl-2 may correlate to the presence of epstein-barr virus genome and the expression of proliferating cell nuclear antigen in nasopharyngeal carcinoma. Cancer Lett. 160:199–208. 2000.PubMed/NCBI View Article : Google Scholar
37	Chou J, Lin YC, Kim J, You L, Xu Z, He B and Jablons DM: Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis. Head Neck. 30:946–963. 2008.PubMed/NCBI View Article : Google Scholar
38	Allday MJ, Sinclair A, Parker G, Crawford DH and Farrell PJ: Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J. 14:1382–1391. 1995.PubMed/NCBI
39	Belcher R, Hayes K, Fedewa S and Chen AY: Current treatment of head and neck squamous cell cancer. J Surg Oncol. 110:551–574. 2014.PubMed/NCBI View Article : Google Scholar
40	Perri F, Della Vittoria Scarpati G, Buonerba C, Di Lorenzo G, Longo F, Muto P, Schiavone C, Sandomenico F and Caponigro F: Combined chemo-radiotherapy in locally advanced nasopharyngeal carcinomas. World J Clin Oncol. 4:47–51. 2013.PubMed/NCBI View Article : Google Scholar